$258 Billion is the total value of Versant Venture Management, LLC's 8 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 11.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | Sell | CRISPR Therapeutics AG | $173,546,331,000 | -13.3% | 4,233,870 | -0.4% | 67.15% | +15.2% |
| VCYT | Sell | Veracyte, Inc. | $28,929,768,000 | -57.9% | 1,205,407 | -50.0% | 11.19% | -44.1% |
| GRTS | Gritstone Oncology, Inc. | $26,793,792,000 | -22.5% | 3,102,929 | 0.0% | 10.37% | +2.9% | |
| BOLD | Audentes Therapeutics, Inc. | $15,559,500,000 | -25.8% | 553,916 | 0.0% | 6.02% | -1.5% | |
| OCUL | Ocular Therapeutix, Inc. | $6,734,767,000 | -30.9% | 2,215,384 | 0.0% | 2.61% | -8.2% | |
| EYES | Second Sight Medical Products, Inc. | $3,706,255,000 | +3.0% | 4,492,975 | 0.0% | 1.43% | +36.8% | |
| CBAY | CymaBay Therapeutics, Inc. | $2,784,014,000 | -28.5% | 543,753 | 0.0% | 1.08% | -5.0% | |
| CLVS | Clovis Oncology, Inc. | $400,290,000 | -73.6% | 101,855 | 0.0% | 0.16% | -64.9% | |
| OPGN | Exit | OpGen, Inc. | $0 | – | -102,167 | -100.0% | -0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-10-08
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-03 |
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.